

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 6,869,924 B1  
APPLICATION NO. : 07/330446  
DATED : March 22, 2005  
INVENTOR(S) : Yoshimura et al.

Page 1 of 2

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Front Page, (\*) Notice, line 3: "by 1,826 days." should read --by 0 days.--

Col. 1, line 18: "thought in include" should read --thought to include--

Col. 2, line 32: "X is pyrolutamic acid." should read --X is pyroglutamic acid.--

Col. 4, line 33: ""The term "LAMBDA" should read --The term "LAMBDA--

Col. 4, line 40: "Calif. 92037."" should read --Calif. 92037.--

Col. 4, line 47: "and extend of determined" should read --and extent of determined--

Col. 8, line 30: "include the B-lactamase" should read --include the  $\beta$ -lactamase"

Col. 9, line 17: "linear Nacl gradients" should read --linear NaCl gradients--

Col. 14, lines 31-32: "Line U-150MG Derived" should read --Line U-105MG Derived--

Col. 17, line 50: "Lambda ZAP II vector" should read --Lambda ZAP II<sup>®</sup> vector--

Col. 18, line 2: "Approximately  $5 \times 10$ " should read --Approximately  $5 \times 10^5$ --

Col. 18, line 34: "cytokines: IL-L $\beta$ , IL-2," should read --cytokines: IL-1 $\beta$ , IL-2,--

Col. 18, line 62: "LAMBDA ZAP II." should read --LAMBDA ZAP II<sup>®</sup>.--

Col. 24, line 27: "X is tyrosine; and" should read --Y is tyrosine; and--

Col. 24, line 28: "Y is pyroglutamic acid." should read --X is pyroglutamic acid.--

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 6,869,924 B1  
APPLICATION NO. : 07/330446  
DATED : March 22, 2005  
INVENTOR(S) : Yoshimura et al.

Page 2 of 2

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Col. 27, line 23, claim 2: "obtained in Step IV" should read --obtained in Step III--

Col. 27, line 28, claim 2: "obtained in Step IV" should read --obtained in Step IV--

Col. 27, line 34, claim 2: "peptide product as" should read --peptide product--

Col. 28, line 6, claim 4: "AVLFKTTYAKEICADPKQKWVQDSMDHLDKRTQTPKT"  
should read --AVIFKTIVAKEICADPKQKWVQDSMDHLDKRTQTPKT--


Col. 28, line 24, claim 4: delete duplicate "or conservative amino acid substitutions thereof."

Col. 28, line 53, claim 6: "an no acid sequence" should read -- an amino acid sequence--

Col. 30, line 15, claim 10: "appropriate cation change" should read --appropriate cation-exchange--

Signed and Sealed this

Twenty-second Day of August, 2006

A handwritten signature in black ink, appearing to read "Jon W. Dudas". The signature is stylized with a large, looped initial "J" and a distinct "D" at the end.

JON W. DUDAS  
*Director of the United States Patent and Trademark Office*